Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
A clinical guide to the management of Graves' disease with radioactive iodine.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Levetan C, Wartofsky L.
PMID: 15251595
Endocr Pract. 1995 May-Jun;1(3):205-12. doi: 10.4158/EP.1.3.205.

More than 50 years have passed since radioactive iodine (RAI) was initially demonstrated as a therapeutic modality for the treatment of Graves' Disease. Today, more than a million patients have been treated with RAI. RAI is considered safe and...

Cite
Levetan C, Wartofsky L. A clinical guide to the management of Graves' disease with radioactive iodine. Endocr Pract. 1995;1(3):205-12doi: 10.4158/EP.1.3.205.
Levetan, C., & Wartofsky, L. (1995). A clinical guide to the management of Graves' disease with radioactive iodine. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 1(3), 205-12. https://doi.org/10.4158/EP.1.3.205
Levetan, C, and Wartofsky, L. "A clinical guide to the management of Graves' disease with radioactive iodine." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 1,3 (1995): 205-12. doi: https://doi.org/10.4158/EP.1.3.205
Levetan C, Wartofsky L. A clinical guide to the management of Graves' disease with radioactive iodine. Endocr Pract. 1995 May-Jun;1(3):205-12. doi: 10.4158/EP.1.3.205. PMID: 15251595.
Copy Download .nbib Format: NLM
Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity.

American journal of surgery

Zheng H, Lai V, Lu J, Kang JK, Felger EA, Carroll NM, Burman KD, Wartofsky L, Rosen JE.
PMID: 34600740
Am J Surg. 2021 Sep 29; doi: 10.1016/j.amjsurg.2021.09.018. Epub 2021 Sep 29.

BACKGROUND: Few studies have compared the features of thyroid cancer among races and ethnicities. We hypothesized that race and ethnicity may influence the frequency and features of thyroid malignancy in thyroid nodules.METHOD: This was a retrospective chart review of...

Cite
Zheng H, Lai V, Lu J, et al. Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity. Am J Surg. 2021;doi: 10.1016/j.amjsurg.2021.09.018.
Zheng, H., Lai, V., Lu, J., Kang, J. K., Felger, E. A., Carroll, N. M., Burman, K. D., Wartofsky, L., & Rosen, J. E. (2021). Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity. American journal of surgery, . https://doi.org/10.1016/j.amjsurg.2021.09.018
Zheng, Hui, et al. "Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity." American journal of surgery vol. (2021). doi: https://doi.org/10.1016/j.amjsurg.2021.09.018
Zheng H, Lai V, Lu J, Kang JK, Felger EA, Carroll NM, Burman KD, Wartofsky L, Rosen JE. Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity. Am J Surg. 2021 Sep 29; doi: 10.1016/j.amjsurg.2021.09.018. Epub 2021 Sep 29. PMID: 34600740.
Copy Download .nbib Format: NLM
Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas.

Cancers

Ylli D, Patel A, Jensen K, Li ZZ, Mendonca-Torres MC, Costello J, Gomes-Lima CJ, Wartofsky L, Burman KD, Vasko VV.
PMID: 31810221
Cancers (Basel). 2019 Dec 02;11(12). doi: 10.3390/cancers11121916.

We examined the utility of microfluidic digital PCR (dPCR) for detection of

Cite
Ylli D, Patel A, Jensen K, et al. Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas. Cancers (Basel). 2019;11(12)doi: 10.3390/cancers11121916.
Ylli, D., Patel, A., Jensen, K., Li, Z. Z., Mendonca-Torres, M. C., Costello, J., Gomes-Lima, C. J., Wartofsky, L., Burman, K. D., & Vasko, V. V. (2019). Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas. Cancers, 11(12), . https://doi.org/10.3390/cancers11121916
Ylli, Dorina, et al. "Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas." Cancers vol. 11,12 (2019). doi: https://doi.org/10.3390/cancers11121916
Ylli D, Patel A, Jensen K, Li ZZ, Mendonca-Torres MC, Costello J, Gomes-Lima CJ, Wartofsky L, Burman KD, Vasko VV. Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas. Cancers (Basel). 2019 Dec 02;11(12). doi: 10.3390/cancers11121916. PMID: 31810221; PMCID: PMC6966523.
Copy Download .nbib Format: NLM
Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al.

Frontiers in neuroendocrinology

Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS.
PMID: 24268499
Front Neuroendocrinol. 2014 Jan;35(1):2-5. doi: 10.1016/j.yfrne.2013.09.003. Epub 2013 Nov 21.

No abstract available.

Cite
Gore AC, Balthazart J, Bikle D, et al. Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al. Front Neuroendocrinol. 2013;35(1):2-5doi: 10.1016/j.yfrne.2013.09.003.
Gore, A. C., Balthazart, J., Bikle, D., Carpenter, D. O., Crews, D., Czernichow, P., Diamanti-Kandarakis, E., Dores, R. M., Grattan, D., Hof, P. R., Hollenberg, A. N., Lange, C., Lee, A. V., Levine, J. E., Millar, R. P., Nelson, R. J., Porta, M., Poth, M., Power, D. M., Prins, G. S., Ridgway, E. C., Rissman, E. F., Romijn, J. A., Sawchenko, P. E., Sly, P. D., Söder, O., Taylor, H. S., Tena-Sempere, M., Vaudry, H., Wallen, K., Wang, Z., Wartofsky, L., & Watson, C. S. (2014). Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al. Frontiers in neuroendocrinology, 35(1), 2-5. https://doi.org/10.1016/j.yfrne.2013.09.003
Gore, A C, et al. "Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al." Frontiers in neuroendocrinology vol. 35,1 (2014): 2-5. doi: https://doi.org/10.1016/j.yfrne.2013.09.003
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al. Front Neuroendocrinol. 2014 Jan;35(1):2-5. doi: 10.1016/j.yfrne.2013.09.003. Epub 2013 Nov 21. PMID: 24268499.
Copy Download .nbib Format: NLM
Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy.

Journal of clinical medicine

Jensen K, Thakur S, Patel A, Mendonca-Torres MC, Costello J, Gomes-Lima CJ, Walter M, Wartofsky L, Burman KD, Bikas A, Ylli D, Vasko VV, Klubo-Gwiezdzinska J.
PMID: 32748840
J Clin Med. 2020 Aug 02;9(8). doi: 10.3390/jcm9082481.

The detection of rare mutational targets in plasma (liquid biopsy) has emerged as a promising tool for the assessment of patients with cancer. We determined the presence of cell-free DNA containing the

Cite
Jensen K, Thakur S, Patel A, et al. Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy. J Clin Med. 2020;9(8)doi: 10.3390/jcm9082481.
Jensen, K., Thakur, S., Patel, A., Mendonca-Torres, M. C., Costello, J., Gomes-Lima, C. J., Walter, M., Wartofsky, L., Burman, K. D., Bikas, A., Ylli, D., Vasko, V. V., & Klubo-Gwiezdzinska, J. (2020). Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy. Journal of clinical medicine, 9(8), . https://doi.org/10.3390/jcm9082481
Jensen, Kirk, et al. "Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy." Journal of clinical medicine vol. 9,8 (2020). doi: https://doi.org/10.3390/jcm9082481
Jensen K, Thakur S, Patel A, Mendonca-Torres MC, Costello J, Gomes-Lima CJ, Walter M, Wartofsky L, Burman KD, Bikas A, Ylli D, Vasko VV, Klubo-Gwiezdzinska J. Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy. J Clin Med. 2020 Aug 02;9(8). doi: 10.3390/jcm9082481. PMID: 32748840; PMCID: PMC7464493.
Copy Download .nbib Format: NLM
Sex Differences in Differentiated Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association

Shobab L, Burman KD, Wartofsky L.
PMID: 34969307
Thyroid. 2021 Dec 31; doi: 10.1089/thy.2021.0361. Epub 2021 Dec 31.

Sex dimorphism strongly impacts tumor biology with most cancers having a male predominance. Uniquely, thyroid cancer is the only non-reproductive cancer with striking female predominance with 3-4-fold higher incidence among females, although males generally have more aggressive disease. The...

Cite
Shobab L, Burman KD, Wartofsky L. Sex Differences in Differentiated Thyroid Cancer. Thyroid. 2021;doi: 10.1089/thy.2021.0361.
Shobab, L., Burman, K. D., & Wartofsky, L. (2021). Sex Differences in Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, . https://doi.org/10.1089/thy.2021.0361
Shobab, Leila, et al. "Sex Differences in Differentiated Thyroid Cancer." Thyroid : official journal of the American Thyroid Association vol. (2021). doi: https://doi.org/10.1089/thy.2021.0361
Shobab L, Burman KD, Wartofsky L. Sex Differences in Differentiated Thyroid Cancer. Thyroid. 2021 Dec 31; doi: 10.1089/thy.2021.0361. Epub 2021 Dec 31. PMID: 34969307.
Copy Download .nbib Format: NLM
Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen.

Journal of thyroid research

Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L.
PMID: 21876837
J Thyroid Res. 2011;2011:843591. doi: 10.4061/2011/843591. Epub 2011 Aug 25.

The prevalence of overt and subclinical hypothyroidism during pregnancy is estimated to be 0.3-0.5% and 2-3%, respectively. Thyroid autoantibodies are found in 5-18% of women in the childbearing age. The aim of this review is to underscore the clinical...

Cite
Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen. J Thyroid Res. 2011;2011:843591doi: 10.4061/2011/843591.
Klubo-Gwiezdzinska, J., Burman, K. D., Van Nostrand, D., & Wartofsky, L. (2011). Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen. Journal of thyroid research, 2011843591. https://doi.org/10.4061/2011/843591
Klubo-Gwiezdzinska, Joanna, et al. "Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen." Journal of thyroid research vol. 2011 (2011): 843591. doi: https://doi.org/10.4061/2011/843591
Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L. Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen. J Thyroid Res. 2011;2011:843591. doi: 10.4061/2011/843591. Epub 2011 Aug 25. PMID: 21876837; PMCID: PMC3163038.
Copy Download .nbib Format: NLM
Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer.

European thyroid journal

Choudhary C, Wartofsky L, Tefera E, Burman KD.
PMID: 26279996
Eur Thyroid J. 2015 Jun;4(2):106-14. doi: 10.1159/000431317. Epub 2015 Jun 11.

OBJECTIVES: We conducted a retrospective chart review of patients with differentiated thyroid cancer who underwent total thyroidectomy to examine the correlation of the persistence of thyroid bed nodules seen on ultrasonography with subsequent loco-regional recurrence.METHODS: A total of 60...

Cite
Choudhary C, Wartofsky L, Tefera E, et al. Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer. Eur Thyroid J. 2015;4(2):106-14doi: 10.1159/000431317.
Choudhary, C., Wartofsky, L., Tefera, E., & Burman, K. D. (2015). Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer. European thyroid journal, 4(2), 106-14. https://doi.org/10.1159/000431317
Choudhary, Chitra, et al. "Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer." European thyroid journal vol. 4,2 (2015): 106-14. doi: https://doi.org/10.1159/000431317
Choudhary C, Wartofsky L, Tefera E, Burman KD. Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer. Eur Thyroid J. 2015 Jun;4(2):106-14. doi: 10.1159/000431317. Epub 2015 Jun 11. PMID: 26279996; PMCID: PMC4521061.
Copy Download .nbib Format: NLM
A rose by any name surely does smell just as sweetly: The controversy over revised nomenclature for encapsulated follicular variant papillary carcinoma.

Journal of translational internal medicine

Wartofsky L.
PMID: 28191520
J Transl Int Med. 2016 Jun 01;4(2):55-57. doi: 10.1515/jtim-2016-0023. Epub 2016 Jul 07.

No abstract available.

Cite
Wartofsky L. A rose by any name surely does smell just as sweetly: The controversy over revised nomenclature for encapsulated follicular variant papillary carcinoma. J Transl Int Med. 2016;4(2):55-57doi: 10.1515/jtim-2016-0023.
Wartofsky, L. (2016). A rose by any name surely does smell just as sweetly: The controversy over revised nomenclature for encapsulated follicular variant papillary carcinoma. Journal of translational internal medicine, 4(2), 55-57. https://doi.org/10.1515/jtim-2016-0023
Wartofsky, Leonard. "A rose by any name surely does smell just as sweetly: The controversy over revised nomenclature for encapsulated follicular variant papillary carcinoma." Journal of translational internal medicine vol. 4,2 (2016): 55-57. doi: https://doi.org/10.1515/jtim-2016-0023
Wartofsky L. A rose by any name surely does smell just as sweetly: The controversy over revised nomenclature for encapsulated follicular variant papillary carcinoma. J Transl Int Med. 2016 Jun 01;4(2):55-57. doi: 10.1515/jtim-2016-0023. Epub 2016 Jul 07. PMID: 28191520; PMCID: PMC5290903.
Copy Download .nbib Format: NLM
Amifostine does not protect thyroid cancer cells in DNA damaging .

Endocrine connections

Klubo-Gwiezdzinska J, Costello J, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V.
PMID: 28790138
Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 08.

BACKGROUND: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer...

Cite
Klubo-Gwiezdzinska J, Costello J, Jensen K, et al. Amifostine does not protect thyroid cancer cells in DNA damaging . Endocr Connect. 2017;6(7):469-478doi: 10.1530/EC-17-0138.
Klubo-Gwiezdzinska, J., Costello, J., Jensen, K., Patel, A., Tkavc, R., Van Nostrand, D., Burman, K. D., Wartofsky, L., & Vasko, V. (2017). Amifostine does not protect thyroid cancer cells in DNA damaging . Endocrine connections, 6(7), 469-478. https://doi.org/10.1530/EC-17-0138
Klubo-Gwiezdzinska, Joanna, et al. "Amifostine does not protect thyroid cancer cells in DNA damaging ." Endocrine connections vol. 6,7 (2017): 469-478. doi: https://doi.org/10.1530/EC-17-0138
Klubo-Gwiezdzinska J, Costello J, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V. Amifostine does not protect thyroid cancer cells in DNA damaging . Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 08. PMID: 28790138; PMCID: PMC5597971.
Copy Download .nbib Format: NLM
Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes.

Journal of the Endocrine Society

Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD.
PMID: 30706042
J Endocr Soc. 2018 Nov 21;3(2):359-371. doi: 10.1210/js.2018-00241. eCollection 2019 Feb 01.

BACKGROUND AND OBJECTIVE: The brain is an unusual site for distant metastases of differentiated thyroid carcinoma (DTC). The aim of this study was to document the prevalence of brain metastases from DTC at our institutions and to analyze the...

Cite
Gomes-Lima CJ, Wu D, Rao SN, et al. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. J Endocr Soc. 2018;3(2):359-371doi: 10.1210/js.2018-00241.
Gomes-Lima, C. J., Wu, D., Rao, S. N., Punukollu, S., Hritani, R., Zeymo, A., Deeb, H., Mete, M., Aulisi, E. F., Van Nostrand, D., Jonklaas, J., Wartofsky, L., & Burman, K. D. (2019). Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. Journal of the Endocrine Society, 3(2), 359-371. https://doi.org/10.1210/js.2018-00241
Gomes-Lima, Cristiane J, et al. "Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes." Journal of the Endocrine Society vol. 3,2 (2019): 359-371. doi: https://doi.org/10.1210/js.2018-00241
Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. J Endocr Soc. 2018 Nov 21;3(2):359-371. doi: 10.1210/js.2018-00241. eCollection 2019 Feb 01. PMID: 30706042; PMCID: PMC6348752.
Copy Download .nbib Format: NLM
Statement of principle.

Endocrine reviews

Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ.
PMID: 25365740
Endocr Rev. 2014 Dec;35(6):850. doi: 10.1210/er.2014-1089. Epub 2014 Nov 03.

No abstract available.

Cite
Cefalu WT, Nair KS, Seaquist ER, et al. Statement of principle. Endocr Rev. 2014;35(6):850doi: 10.1210/er.2014-1089.
Cefalu, W. T., Nair, K. S., Seaquist, E. R., Zierath, J., Boulton, A. J., LeRoith, D., Harrell, R. M., Grunberger, G., Wartofsky, L., Gore, A. C., Wierman, M. E., Hammes, S. R., Lange, C. A., & Santen, R. J. (2014). Statement of principle. Endocrine reviews, 35(6), 850. https://doi.org/10.1210/er.2014-1089
Cefalu, William T, et al. "Statement of principle." Endocrine reviews vol. 35,6 (2014): 850. doi: https://doi.org/10.1210/er.2014-1089
Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. Endocr Rev. 2014 Dec;35(6):850. doi: 10.1210/er.2014-1089. Epub 2014 Nov 03. PMID: 25365740.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries